Aleksander M. Ishchenko

Aleksander M. Ishchenko

Auto-generated profile, based on publicly available information

Aleksander M. Ishchenko

Saint Petersburg Pasteur Institute

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
INInga Nazarova
Inga Nazarova
LZLidia Zabegina
Lidia Zabegina
Nadezhda NikiforovaNadezhda Nikiforova
Nadezhda Nikiforova
MSMaria Slyusarenko
Maria Slyusarenko
ESE. I. Sidina
E. I. Sidina
Anastasia MalekAnastasia Malek
Anastasia Malek
Background. Heat stress (HS) induces the cellular secretion of heat shock proteins (HSP ) and extracellular nanovesicles (ENVs). The biological link between these phenomena is poorly understood. In the case of colorectal cancer (CRC) cells, the secretion of HSP s and ENV may be involved in the clinical response to intraperitoneal therapy of peritoneal carcinomatosis.Material and Methods. Established colon cancer cell lines COLO 320, HCT 116, HT29 and DLD 1 were used. ENVs were isolated from culture media by differential ultra-centrifugation and analyzed by dynamic light scattering, nanoparticle tracking analysis, atomic force microscopy and flow cytometry. Super-paramagnetic particles (SPMP ) covered by antibodies to the membrane form of Hsp70 were used for isolation and quantification of Hsp70(+) ENVs. Vesicular microRNA was assayed by RT-qPC R.Results. HS induces the secretion of ENVs by CRC cells, the resistance to HS correlates with the activity of HS-induced ENVs secretion. HS induces the secretion of a specific population of ENVs enriched by membrane form Hsp70 (mHsp70). The microRNA content of mHsp70(+) ENVs has qualitative and quantitative features. The concentration of miR-126-3p, -181-5p, -155-5p, -223 is increased in mHSP 70(+) ENVs secreted by three CRC cell lines.Conclusion. HS induces the secretion of mHSP 70(+) ENVs by CRC cells. This phenomenon may be involved in a clinical response to intraperitoneal chemo-hyperthermic perfusion therapy of peritoneal carcinomatosis.

1 June 2023 in Medical Immunology (Russia)
Verified
Journal Article
Open access
PDF file
NGNikolay Gorbunov
Nikolay Gorbunov
AZA. V. Zhakhov
A. V. Zhakhov
IGI. N. Gorbunova
I. N. Gorbunova
AMA. M. Milichkina
A. M. Milichkina
IDI. V. Drozd
I. V. Drozd
ATAreg A. Totolian
Areg A. Totolian
C1 inhibitor of serine proteases (C1-INH) performs a regulatory function in the complement system and vascular permeability. Deficiency of C1-INH leads to various forms of angioedema, including hereditary angioedema (HAE). The cause of HAE is a genetically determined violation of the synthesis of C1-INH. A decrease in the level of C1-INH to 50% relative to the norm leads to an increase in the production of bradykinin, which is the basis for the diagnosis of HAE. The development of affordable ELISA for the quantitative determination of C1-INH is a popular direction for clinicians. During the development of a new kit for quantitative determination of C1-INH, two mouse monoclonal antibodies (mAb) with different epitope specificities were obtained. On their basis, a sandwich-type ELISA was developed. The specificity of the obtained mAb's was confirmed using the medical device “Berinert”. To prepare calibrators, C1-INH was affinity purified from human blood plasma using a sorbent with immobilized mAbs. The identity of the C1-INH protein was confirmed by PAGE electrophoresis, immunoblotting, and mass spectrometry on MALDI-TOF/TOF UltrafleXtreme mass spectrometer. To assess the quality indicators of developed reagents kit, studies were carried out in accordance with GOST R 51352-2013 and TU 21.20.23-041-01967164-2022. Values of quality indicators: accuracy — 93.53%; measurement linearity interval — 22.00-176.07 ng/mL. Using the developed ELISA test system, we examined 28 blood sera from healthy donors and 7 blood sera from patients with confirmed HAE. In the same samples, the content of C1-INH was determined by turbidimetric method, using the "Diagnostic reagents for in vitro immunochemical studies of specific blood proteins. Model: C1-esterase inhibitor (C1 EsteraseInhibitor)" (Aptec, Belgium). The correlation coefficient was 0.94 (p < 0.05). It was found that the diagnostic sensitivity and specificity of the developed ELISA is 100%. As a result of the study, an original ELISA test system for the quantitative determination of C1-INH was developed "Reagent kit for enzyme-linked immunosorbent assay of human C1-inhibitor (C1-inh PS)".

25 December 2024 in Medical academic journal
Verified
Journal Article
Closed access
PDF file
TFTatiana A. Filatenkova
Tatiana A. Filatenkova
SSSergey N. Shanin
Sergey N. Shanin
EFElena E. Fomicheva
Elena E. Fomicheva
AIAleksander M. Ishchenko
Aleksander M. Ishchenko
NSNatalia B. Serebryanaya
Natalia B. Serebryanaya
СБСеребряная Наталья Борисовна
Серебряная Наталья Борисовна
BACKGROUND: Chronic fatigue after a viral infection is common, and physical weakness is accompanied by cognitive impairment, leading to a decrease in the individual’s quality of life, loss of working capacity and, as a result, depression. Effective treatment methods have not yet been developed. AIM: Therefore, the aim of this study was to identify the possibility of fatigue correction with a recombinant cytokine IL-1 receptor antagonist in an experimental model of post-viral chronic fatigue syndrome in rats. MATERIALS AND METHODS: The work was performed on male Wistar rats; experimental chronic fatigue syndrome was induced by a single injection of polyinosinic:polycytidylic acid. We analyzed changes in behavioral reactions, the level of physical activity (degree of fatigue), changes in lactate concentration in blood and the expression of IL-1β, IL-10, INFα, 5-HTT, TLR3 genes in hypothalamus, and also assessed the splenocytes cytotoxic and proliferative activity. RESULTS: Medication of IL-1 receptor antagonist leads to improved physical activity, a decrease in the concentration of lactat in the blood serum and a decrease in anxiety compared to untreated animals, which may indicate a milder course of chronic fatigue syndrome during the period of its maximum manifestations. Inhibition of peripheral cells of the immune system after administration of polyinosinic:polycytidylic acid and correction of this parameter with IL-1 receptor antagonist were shown. On the 10th day of the experiment, all parameters in the group of treated rats normalized and only TLR3 expression still remained elevated at the level of untreated rats which is regarded as activation of reparation processes. CONCLUSIONS: The obtained data indicate that the use of the recombinant IL-1 receptor antagonist alleviates the manifestations of post-viral chronic fatigue syndrome in rats and completes the pathological process at an earlier date. With a recombinant IL-1 receptor antagonist is included in the treatment regimen for chronic fatigue syndrome in humans, positive results can also be expected.

15 September 2024 in Cytokines and inflammation
Verified
Journal Article
Closed access
PDF file
AIAlexander M. Ischenko
Alexander M. Ischenko
KNKseniya A. Nekrasova
Kseniya A. Nekrasova
DLDenis S. Laptev
Denis S. Laptev
DBDmitry V. Bobkov
Dmitry V. Bobkov
AKAlexander A. Kolobov
Alexander A. Kolobov
СССимбирцев Андрей Семенович
Симбирцев Андрей Семенович
BACKGROUND: The severity of respiratory distress syndrome is associated with the development of systemic multifactorial inflammatory processes leading to hyperinflammation. Proinflammatory cytokines, primarily interleukin-1 (IL-1), and reactive oxygen species substantially contribute to these pathological processes. The use of an interleukin-1 receptor antagonist (IL-1Ra) as an IL-1 blocker is a key first-line therapy for patients experiencing cytokine storm syndrome. The novelty of the approach under investigation lies in studying the effectiveness of inhaled administration of IL-1Ra, including its combined use with a reactive oxygen species inhibitor — superoxide dismutase (SOD). AIM: To assess the efficacy of IL-1Ra administered parenterally and by inhalation, both as a standalone agent and in combination with SOD, in a bleomycin-induced acute respiratory distress syndrome model. MATERIALS AND METHODS: Male BALB/c mice were used in the study. Respiratory distress syndrome was modeled by intraperitoneal administration of bleomycin at a dose of 2 mg/mouse on days 1, 8, and 15 of the experiment. The investigational drugs—a 10.0-mg/mL IL-1Ra solution and a 10.0-mg/mL IL-1Ra solution containing 0.4 mg/mL SOD—were administered to the experimental groups either subcutaneously or by inhalation at a dose of 2 mg/mouse daily for 15 days starting from day 1 of the experiment. Body weight, spirometry, histological studies, and animal survival were assessed. RESULTS: Subcutaneous and inhalation administration of IL-1Ra + SOD, as well as subcutaneous administration of IL-1Ra, positively affected animal survival. Subcutaneous administration of IL-1Ra and IL-1Ra + SOD led to statistically significant improvements in indicators of external respiration in mice with bleomycin-induced intoxication. A reduction in destructive lung changes caused by intraperitoneal administration of bleomycin was observed in the experimental groups receiving inhaledIL-1Ra orIL-1Ra + SOD and in the group receiving subcutaneous IL-1Ra. CONCLUSION: Both investigational products — IL-1Ra and IL-1Ra + SOD — administered by injection or inhalation demonstrated a positive effect in the treatment of respiratory distress syndrome induced by bleomycin in the mouse model.

25 December 2025 in Medical academic journal
Verified
Journal Article
Closed access
PDF file
ADA. S. Dyatlova
A. S. Dyatlova
NNN. S. Novikova
N. S. Novikova
TFT. A. Filatenkova
T. A. Filatenkova
SSS. N. Shanin
S. N. Shanin
EFE. E. Fomicheva
E. E. Fomicheva
ИМИщенко Александр Митрофанович
Ищенко Александр Митрофанович
BACKGROUND: A traumatic brain injury causes both primary brain damage and secondary inflammation. This inflammation can contribute to further neuronal damage and dysfunction. Microglial cells are key players in neuroinflammation, which can remain activated for a long time after a traumatic brain injury. Microglial cells are the main source of elevated interleukin-1β (IL-1β) levels in the brain after traumatic brain injury. Therefore, it is essential to investigate their status following the administration of a recombinant IL-1 receptor antagonist (rIL-1Ra), particularly in the long term. The study tested the hypothesis that administration of an IL-1 receptor antagonist during the early post-traumatic period would sufficiently reduce neuroinflammatory activity 30 days after traumatic brain injury. AIM: The study aimed to evaluate the effect of rIL-1Ra on morphological characteristics of microglia in brain areas susceptible to injury, as well as to assess gene expression of neurotrophic factors Bdnf, Ngf, and Vegf and the inflammatory marker S100a12 in the hypothalamus as a potential structure with secondary inflammation on day 30 after traumatic brain injury. METHODS: A drop-weight model was used to induce a diffuse brain injury, and rIL-1Ra was administered subcutaneously at 50 mg/kg one hour after traumatic brain injury, and then twice more over the next two days. Microglial cell activation was assessed using immunohistochemistry and morphometry. The expression of Bdnf, Ngf, Vegf, and S100a12 was determined using a real-time polymerase chain reaction. RESULTS: On day 30 after injury, there were no significant changes in hypothalamic gene expression of neurotrophic factors (Bdnf, Ngf) or S100a12. However, a significant increase in Vegf expression was observed in animals that received rIL-1Ra. Immunohistochemistry showed that activated microglial cells remained in some areas of the brain after treatment, but their numbers were substantially reduced compared to the untreated injured animals. CONCLUSION: rIL-1Ra influences the inflammatory response to traumatic brain injury by reducing microglial activity and enhancing neurotrophic processes. These findings suggest the potential of using rIL-1Ra to treat the sequelae of traumatic brain injury.